A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Enrollment status: Open
Prurigo nodularis (PN), is a chronic itchy skin condition characterized by multiple raised bumps in the skin called “nodules". There is no one specific cause of purigo nodularis. We are studying an investigational drug called nemolizumab as a possible treatment. Nemolizumab is a type of biological drug called a monoclonal antibody. It blocks the binding of interleukin-31 (an immune system signaling molecule produced by the body) to its receptor. By blocking the binding, nemolizumab is expected to break the itch-scratch cycle and allow the skin to heal. The main purpose of this research study is to learn how effective (how well it works) and safe the study drug is which will be determined by how our subjects respond to treatment.
Study coordinator: Nicole Nechiporchik, (734) 232-0562 or [email protected]
Please reference Derm #: 740